The role of antiangiogenic agents in the treatment of gastric cancer: A systematic review and meta-analysis.
The role of antiangiogenic agents in the treatment of gastric cancer: A systematic review and meta-analysis.
复制标题
抗血管生成药物在胃癌治疗中的作用系统评价和荟萃分析
DOI：
10.1097/md.0000000000006301
复制
发表时间：
2017-03
期刊：
影响因子：
1.6
通讯作者：
Wang L
中科院分区：
文献类型：
--
作者：
Lei X;Wang F;Ke Y;Wei D;Gu H;Zhang Z;Jiang L;Lv L;Lin J;Wang L
进展期胃癌的生存率很低，抗血管生成药物的疗效尚无定论。本研究的目的是评估联合化疗与抗血管生成治疗与传统化疗。为了达到科学严谨的目标，从参考作品和实验的统计数据进行了分析。我们通过检索和分析文献数据库，仔细检索了与治疗GC患者的其他治疗方法相比，抗血管生成治疗的参考文献。实验分为两组：实验组和对照组。实验组给予抗血管生成药物治疗，对照组给予标准化疗或安慰剂治疗。该研究共包括3240名参与者。总体而言，与标准化疗组或安慰剂组相比，抗血管生成药物组的总生存期（风险比[HR]= 0.78，95%置信区间[CI]：0.67-0.91，P = 0.002）、无进展生存期（HR 0.65，95% CI：0.52-0.81，P = 0.0002）、客观缓解率（风险比[RR]= 1.58，95% CI：1.33-1.88，P <0.00001）和疾病控制率（RR 2.44，95% CI：1.57-3.78，P <0.0001）均有显著改善。 此外，这种新的治疗方法显示出可耐受的毒性。本研究证实，与传统化疗方案相比，联合抗血管生成药物治疗GC患者的上级疗效。此外，这种新的治疗方法显示出可耐受的毒性。这项荟萃分析为那些对使用抗血管生成疗法治疗GC患者感兴趣的临床医生提供了重要信息。
The survival of advanced gastric cancer (GC) is dismal, and effects of antiangiogenic agents remain inconclusive. The purpose of this study is to assess combination of chemotherapy with antiangiogenic therapy versus traditional chemotherapy. To achieve the goal of scientific rigor, statistics from both referenced works and experiments were analyzed. We carefully searched for the referenced works by retrieving, as well as analyzing, literature databases for information on antiangiogenic therapy compared to other therapeutic approaches used to treat GC patients. Two groups were defined in the experiment: experimental and control groups. The experimental group was treated with antiangiogenic drug, and the control group was treated with standard chemotherapy or placebo. The study included a total of 3240 participants. Overall, there was significant improvement in overall survival (hazard ratio [HR] = 0.78, 95% confidence interval [CI]: 0.67–0.91, P = 0.002), progression-free survival (HR 0.65, 95% CI: 0.52–0.81, P = 0.0002), objective response rate (risk ratio [RR] = 1.58, 95% CI: 1.33–1.88, P < 0.00001), and disease control rate (RR 2.44, 95% CI: 1.57–3.78, P < 0.0001) in the group with antiangiogenic drug versus the group with standard chemotherapy or placebo. Moreover, this new treatment approach showed tolerable toxicity. This study confirms the superior efficacy of combination therapy with antiangiogenic agents in comparison to traditional chemotherapy regimens for patients with GC. Moreover, this new treatment approach showed tolerable toxicity. This meta-analysis provides important information for clinicians who are interested in using antiangiogenic therapies to treat GC patients.